|
summary: Glatiramer acetate is one of the accepted treatments for relapsing-remitting MS (RRMS), but its efficacy after a first relapse has not yet been demonstrated. With a randomised, multicentre, double-blind placebo-controlled clinical trial, the authors demonstrated that GA significantly delays the appearance of a second relapse when given after a first episode. These results may have important consequences from the point of view of clinical practice.
authors: Comi G, Martinelli V, Rodegher M, Moiola L, Bajenaru O, Carra A, Elovaara I, Fazekas F, Hartung H, Hillert J, King J, Komoly S, Lubetzki C, Montalban X, Myhr K, Ravnborg M, Rieckmann P, Wynn D, Young C, Filippi M; for the PreCISe study group
source: Lancet. 2009 Oct 6
weblink: click here
category: Clinical Trials and Therapeutics
related research news: click here
glossary:
ACE
Clinical trial
Glatiramer
Multiple sclerosis
Physical
Placebo
Randomised
Relapse
Relapsing/remitting MS
Sclerosis
Sign
|
